dc.contributor.author | Tahghighi, A | |
dc.contributor.author | Razmi, S | |
dc.contributor.author | Mahdavi, M | |
dc.contributor.author | Foroumadi, P | |
dc.contributor.author | Ardestani, SK | |
dc.contributor.author | Emami, S | |
dc.contributor.author | Kobarfard, F | |
dc.contributor.author | Dastmalchi, S | |
dc.contributor.author | Shafiee, A | |
dc.contributor.author | Foroumadi, A | |
dc.date.accessioned | 2018-08-26T09:37:17Z | |
dc.date.available | 2018-08-26T09:37:17Z | |
dc.date.issued | 2012 | |
dc.identifier.uri | http://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/58085 | |
dc.description.abstract | A novel series of 5-(5-nitrofuran-2-yl)-1,3,4-thiadiazol-2-amines were synthesized by introducing N-[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl] moiety as a new functionality on the C-2 amine of thiadiazole ring via click chemistry. The title compounds namely, N-[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]-5-(5- nitrofuran-2-yl)-1,3,4-thiadiazol-2-amines (3a-n) were characterized by IR, NMR and MS spectra. These compounds were evaluated for their in vitro anti-leishmanial activity against promostigote form of the Leishmania major. Most compounds exhibited good anti-leishmanial activity against the promastigote form of L. major. The most active compound against promostigotes was found to be 4-methylbenzyl analog 3i, which significantly decreases the number of intracellular amastigotes per macrophage, percentage of macrophage infectivity and infectivity index. © 2012 Elsevier Masson SAS. All rights reserved. | |
dc.language.iso | English | |
dc.relation.ispartof | European Journal of Medicinal Chemistry | |
dc.subject | 5 (5 nitrofuran 2 yl) 1,3,4 thiadiazol 2 amine derivative | |
dc.subject | amine | |
dc.subject | antileishmanial agent | |
dc.subject | benzyl derivative | |
dc.subject | n ((1 (2 chloro 6 fluorobenzyl) 1h 1,2,3 triazol 4 yl)methyl) 5 (5 nitrofuran 2 yl) 1,3,4 thiadiazol 2 amine | |
dc.subject | n ((1 (2 chlorobenzyl) 1h 1,2,3 triazol 4 yl)methyl) 5 (5 nitrofuran 2 yl) 1,3,4 thiadiazol 2 amine | |
dc.subject | n ((1 (2 Fluorobenzyl) 1h 1,2,3 triazol 4 yl)methyl) 5 (5 nitrofuran 2 yl) 1,3,4 thiadiazol 2 amine | |
dc.subject | n ((1 (2 methylbenzyl) 1h 1,2,3 triazol 4 yl)methyl) 5 (5 nitrofuran 2 yl) 1,3,4 thiadiazol 2 amine | |
dc.subject | n ((1 (2,3 dichlorobenzyl) 1h 1,2,3 triazol 4 yl)methyl) 5 (5 nitrofuran 2 yl) 1,3,4 thiadiazol 2 amine | |
dc.subject | n ((1 (2,4 dichlorobenzyl) 1h 1,2,3 triazol 4 yl)methyl) 5 (5 nitrofuran 2 yl) 1,3,4 thiadiazol 2 amine | |
dc.subject | n ((1 (3 chlorobenzyl) 1h 1,2,3 triazol 4 yl)methyl) 5 (5 nitrofuran 2 yl) 1,3,4 thiadiazol 2 amine | |
dc.subject | n ((1 (3 methylbenzyl) 1h 1,2,3 triazol 4 yl)methyl) 5 (5 nitrofuran 2 yl) 1,3,4 thiadiazol 2 amine | |
dc.subject | n ((1 (3,4 dichlorobenzyl) 1h 1,2,3 triazol 4 yl)methyl) 5 (5 nitrofuran 2 yl) 1,3,4 thiadiazol 2 amine | |
dc.subject | n ((1 (4 chlorobenzyl) 1h 1,2,3 triazol 4 yl)methyl) 5 (5 nitrofuran 2 yl) 1,3,4 thiadiazol 2 amine | |
dc.subject | n ((1 (4 fluorobenzyl) 1h 1,2,3 triazol 4 yl)methyl) 5 (5 nitrofuran 2 yl) 1,3,4 thiadiazol 2 amine | |
dc.subject | n ((1 (4 methylbenzyl) 1h 1,2,3 triazol 4 yl)methyl) 5 (5 nitrofuran 2 yl) 1,3,4 thiadiazol 2 amine | |
dc.subject | n ((1 (4 nitrobenzyl) 1h 1,2,3 triazol 4 yl)methyl) 5 (5 nitrofuran 2 yl) 1,3,4 thiadiazol 2 amine | |
dc.subject | n ((1 benzyl 1h 1,2,3 triazol 4 yl)methyl) 5 (5 nitrofuran 2 yl) 1,3,4 thiadiazol 2 amine | |
dc.subject | n [(1 benzyl 1h 1,2,3 triazol 4 yl)methyl] | |
dc.subject | unclassified drug | |
dc.subject | article | |
dc.subject | carbon nuclear magnetic resonance | |
dc.subject | click chemistry | |
dc.subject | drug activity | |
dc.subject | drug synthesis | |
dc.subject | human | |
dc.subject | in vitro study | |
dc.subject | infection | |
dc.subject | infrared spectroscopy | |
dc.subject | Leishmania major | |
dc.subject | macrophage | |
dc.subject | mass spectrometry | |
dc.subject | nonhuman | |
dc.subject | proton nuclear magnetic resonance | |
dc.subject | Animals | |
dc.subject | Antiprotozoal Agents | |
dc.subject | Cells, Cultured | |
dc.subject | Leishmania major | |
dc.subject | Leishmaniasis | |
dc.subject | Macrophages, Peritoneal | |
dc.subject | Mice | |
dc.subject | Microbial Sensitivity Tests | |
dc.subject | Molecular Structure | |
dc.subject | Structure-Activity Relationship | |
dc.subject | Thiadiazoles | |
dc.subject | Triazoles | |
dc.title | Synthesis and anti-leishmanial activity of 5-(5-nitrofuran-2-yl)-1,3,4- thiadiazol-2-amines containing N-[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl] moieties | |
dc.type | Review | |
dc.citation.volume | 50 | |
dc.citation.spage | 124 | |
dc.citation.epage | 128 | |
dc.citation.index | Scopus | |
dc.identifier.DOI | https://doi.org/10.1016/j.ejmech.2012.01.046 | |